Medical Condition News

RSS

San Antonio residents to gather at The Westin La Cantera Resort for LLS’s Man & Woman of the Year campaign

On April 1, residents of San Antonio will gather at The Westin La Cantera Resort to “Mix & Mingle for a Cure,” from 5:30 to 8:30 pm, to benefit the Leukemia & Lymphoma Society (LLS)’s Man & Woman of the Year campaign.

27 Mar 2010

Depressed Latinos who stigmatize mental illness less likely to take medication: Study

A new, small study of low-income, depressed Latinos finds that those who stigmatize mental illness are less likely than others are to take medication, keep scheduled appointments and control their condition.

27 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

Two EMBEDA video news releases misleading, warns FDA DDMAC

On October 8, 2009, King Pharmaceuticals, Inc. received a Warning Letter from the Division of Drug Marketing, Advertising, and Communications (DDMAC) at the Food and Drug Administration regarding two video news releases - EMBEDA Media backgrounder, and EMBEDA Visual Media Technology, for EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use C-II.

27 Mar 2010

READ 3 study for DME begins enrolling participants

A Phase II clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.

27 Mar 2010

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

American Academy of Dermatology Association (AADA) President and dermatologist William D. James, MD, FAAD, along with other dermatologists and leading researchers today testified before a Food and Drug Administration (FDA) panel considering changes to the current classification of indoor tanning devices. Currently, the FDA classifies indoor tanning devices as Class 1, the category for items that have minimal potential to cause harm to individuals. Items in Class 1 include adhesive bandages and tongue depressors.

27 Mar 2010

Sutter Solano Cancer Center earns three-year accreditation from ACOS

Sutter Solano Cancer Center has earned a three-year accreditation with six commendations from the Commission on Cancer of the American College of Surgeons. ACOS approval is awarded to centers that have voluntarily committed to providing the highest level of quality cancer care and undergo regular evaluations and reviews of their performance.

27 Mar 2010

Innovative biotechnology leading to better understanding of complex diseases

As recently stated in the Glenville Democrat, innovative biotechnology is leading to a greater understanding of complex diseases and better tools for diagnosing and treating conditions such as heart disease, cancer and diabetes.

27 Mar 2010

New study may give men a way to combat high cholesterol without drugs

A new study from Iowa State University's Nutrition and Wellness Research Center may give men a way to combat high cholesterol without drugs -- if they don't mind sprinkling some flaxseed into their daily diet.

27 Mar 2010

FDA considers tightening restrictions on tanning beds

The Food and Drug Administration may tighten restrictions on tanning beds "amid evidence they raise the risk of skin cancer beyond exposure to ultraviolet radiation from the sun," The Wall Street Journal reports.

27 Mar 2010

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

Graceway® Pharmaceuticals announced today that the Food and Drug Administration has approved the New Drug Application for Zyclara™, determining it to be safe and effective for the treatment of clinically typical, visible or palpable actinic keratoses.

27 Mar 2010

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Cipher Pharmaceuticals Inc. today announced that its New Drug Submission (NDS) to Health Canada for CIP-TRAMADOL ER, its extended-release formulation of tramadol, has been accepted for review. The Company expects the review to be completed by early 2011.

26 Mar 2010

Inflamed tissues linked to increased production of protein involved in pain signaling

Using a novel animal model to study craniofacial pain, researchers at Oregon Health & Science University's School of Dentistry have discovered that when tissues are inflamed, the nerve cells carrying pain information from the head to the brain produce in large quantities a protein involved in pain signaling.

26 Mar 2010

Genetic instability in people with Fanconi anemia: New proteins in FA DNA repair pathway may help explain

Identification of two new proteins in the Fanconi anemia DNA repair pathway may help explain genetic instability in people with Fanconi anemia and how otherwise healthy people are susceptible to cancer from environmentally triggered DNA damage.

26 Mar 2010

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods of treating heart failure patients with bucindolol based on genetic testing.

26 Mar 2010

Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets

Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer® for the treatment of pulmonary arterial hypertension (PAH) in crucial markets throughout Asia. Actelion signed with Invida initially in 2005, and has extended the contract to market the company’s lead product, Tracleer, in Thailand, Malaysia, Philippines, Vietnam, and Hong Kong

26 Mar 2010

Anxiety may rise again, says Rutgers University dean

Poet W.H Auden dubbed the post-World War II nuclear era the "age of anxiety" and indeed, at the time, anxiety disorders were the most commonly diagnosed mental illnesses. Yet, by the 1990s, American psychiatry was "Listening to Prozac" and instead of obsessing about angst, it focused its attention on depression.

26 Mar 2010

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

The Growing Financial Burden Of Health Care: National And State Trends, 2001-2006 - This paper examines the ratio of total out-of-pocket spending for health care and insurance to total family income, using data from the Medical Expenditure Panel Surveys for 2001-2006.

26 Mar 2010

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has filed an Investigational New Drug application for COL-172, a tamper-resistant, extended-release oral opioid formulation intended to treat moderate to severe pain in individuals who require around-the-clock opioid therapy for an extended period of time.

26 Mar 2010

NCMHD announces $3.8M grant for research on minority recruitment in cancer clinical trials

The University of Minnesota Medical School today announced the details of a $3.8 million grant by the National Institutes of Health's National Center on Minority Health and Health Disparities for research focused on minority recruitment and retention in cancer clinical trials.

26 Mar 2010

Medical Condition News

San Antonio residents to gather at The Westin La Cantera Resort for LLS’s Man & Woman of the Year campaign

Depressed Latinos who stigmatize mental illness less likely to take medication: Study

WinRho SDF for ITP: Cangene announces new safety information

Two EMBEDA video news releases misleading, warns FDA DDMAC

READ 3 study for DME begins enrolling participants

Indoor tanning devices: AADA testifies before FDA panel on needed classification changes and calls for ban

Sutter Solano Cancer Center earns three-year accreditation from ACOS

Innovative biotechnology leading to better understanding of complex diseases

New study may give men a way to combat high cholesterol without drugs

FDA considers tightening restrictions on tanning beds

FDA approves Graceway Pharmaceuticals' NDA for Zyclara

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Inflamed tissues linked to increased production of protein involved in pain signaling

Genetic instability in people with Fanconi anemia: New proteins in FA DNA repair pathway may help explain

ARCA biopharma granted patent for methods of treating heart failure patients with bucindolol based on genetic testing

Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets

Anxiety may rise again, says Rutgers University dean

Research Roundup: Middle class health cost burden, disparities and cancer, summary of new health law

Collegium Pharmaceutical files IND for second opioid product using DETERx technology

NCMHD announces $3.8M grant for research on minority recruitment in cancer clinical trials

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News